A method for the inhibition of the binding of 41
integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1)
and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions
comprising such compounds; and to the use of such compounds either a above, or
in formulations for the control or prevention of diseases states in which 41
is involved.